Premium
Venous access closure using a purse‐string suture without heparin antagonism or additional compression after MitraClip implantation
Author(s) -
Akkaya Ersan,
Sözener Korkut,
Rixe Johannes,
Tsiakou Maria,
Souretis Georgios,
Chavakis Emmanouil,
Meyners Werner,
Tanislav Christian,
Gündüz Dursun,
Erkapic Damir
Publication year - 2020
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.28534
Subject(s) - medicine , mitraclip , surgery , pseudoaneurysm , percutaneous , hematoma , vascular closure device , arteriovenous fistula , complication , mitral regurgitation
Abstract Objectives This observational study was designed to analyze the safety and feasibility of percutaneous skin closure using a purse‐string suture (PSS) after MitraClip procedures. Methods Forty‐one consecutive patients with severe mitral regurgitation who underwent MitraClip implantation from February 2018 to January 2019 at our institution received a PSS after percutaneous mitral valve repair before withdrawal of the 24‐French (Fr) sheath. Protamine was not administered after venous closure at procedure end. No compression therapy (e.g., compression bandage or pneumatic compression device) was used. Patients were on bed rest for 6 hrs prior to suture removal, which was accomplished 18–24 hrs after MitraClip implantation. We analyzed the occurrence of any vascular or thromboembolic complications during the hospital stay and until the 3‐month follow‐up. Results The primary endpoint—any access‐related major complication—did not occur in any patients. None of the patients revealed a pseudoaneurysm or an arteriovenous fistula, a thromboembolic complication, or local stenosis related to the PSS closure. The secondary endpoint— minor access‐site vascular complications (hematoma)— was documented in six (14.6%) patients. Conclusions Venous access‐site closure with a PSS without the need for protamine administration or compression therapy appears to be safe and feasible in patients undergoing MitraClip implantation with access via a 24‐Fr sheath.